Jonas Rieth retweetledi
We conducted a phase I #clinicaltrial with CoVac-1, our #peptide-based #COVID19 #vaccine candidate for induction of SARS-CoV-2 T cell immunity. Our observations support the presently ongoing phase II trial for patients with B cell/antibody deficiency. Here’s what we found:
Nature Portfolio@NaturePortfolio
A peptide-based vaccine candidate, called CoVac-1, is shown to induce immunity against SARS-CoV-2 in a phase I clinical trial reported in @Nature. The vaccine candidate induces T cell immunity and could be helpful for people with immunodeficiencies. go.nature.com/30RVRao
English
